Ruxolitinib phosphate

Also known as: Ruxolitinib phosphate, INCB 018424 phosphate, INC 424 phosphate, Jakafi, Jakavi, (3R)-3-Cyclopentyl-3-[4-(1H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile phosphate (1:1), (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate, 1H-Pyrazole-1-propanenitrile, β-cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-, (βR)-, phosphate (1:1)

Ruxolitinib phosphate (CAS 1092939-17-7) is a compound in the Organic Acids category listed in the Jingsj chemical database. It has the molecular formula C17H21N6O4P and a molecular weight of 404.360 g/mol. No supplier offers are currently listed; request a quote. Record last updated Aug 21, 2026.

CAS No.: 1092939-17-7
Jingsj CID: J-1981600-3
Molecular Formula: C₁₇H₂₁N₆O₄P
Molecular Weight: 404.360 g/mol
Category: Organic Acids
Last updated: 8/21/2026

Request MSDS / TDS

No offers for this compound yet.

Request a quote

Physicochemical Properties

Exact Mass	404.136200
PSA	170.75000
LogP	2.53778
Storage Conditions	-20℃

Activity & Biological Data

Target	JAK2:2.8 nM (IC50) JAK1:3.3 nM (IC50) Tyk2:19 nM (IC50) JAK3:428 nM (IC50)
Additional Information	[1]. Quintas-Cardama A, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood, 2010, 115(15), 3109-3117. [2]. Fleischman AG, et al. The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition. Blood. 2013 Nov 21;122(22):3628-31. [3]. de Bock CE, et al. HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development. Cancer Discov. 2018 May;8(5):616-631.

Target

JAK2:2.8 nM (IC50) JAK1:3.3 nM (IC50) Tyk2:19 nM (IC50) JAK3:428 nM (IC50)

Additional Information

[1]. Quintas-Cardama A, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood, 2010, 115(15), 3109-3117. [2]. Fleischman AG, et al. The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition. Blood. 2013 Nov 21;122(22):3628-31. [3]. de Bock CE, et al. HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development. Cancer Discov. 2018 May;8(5):616-631.

Customs & Trade Information

HS Code	2933990090
Summary	2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Frequently Asked Questions

What is the CAS number of Ruxolitinib phosphate?

The CAS number of Ruxolitinib phosphate is 1092939-17-7.

What are the molecular formula and molecular weight of Ruxolitinib phosphate?

Ruxolitinib phosphate has molecular formula C17H21N6O4P and molecular weight 404.360 g/mol.

What are the upstream and downstream products of Ruxolitinib phosphate?

For Ruxolitinib phosphate, Upstream Products: Ruxolitinib, 4-(1H-pyrazol-4-yl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine, 3-Cyclopentylacrylonitrile.

Data compiled from public chemical databases such as PubChem and supplier catalogs; supplier offers are provided by suppliers.

Last updated: 8/21/2026

How to cite: Jingsj. "Ruxolitinib phosphate (CAS 1092939-17-7)". Jingsj Chemical Database. https://www.jingsj.com/compound/J-1981600-3 (accessed 2026-11-09).

Data for reference only; verify product details with suppliers before purchase.